Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this pilot study is to determine the effectiveness of Fluorothymidine Positron Emission Tomography (FLT PET) and Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) in assessing tumour response to neoadjuvant chemotherapy (NA CT) in women with locally advanced breast cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FLT PET and BOLD MRI scan | Other | All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FLT PET and BOLD MRI scan | Procedure | Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical response (partial and complete) | Partial clinical response refers to at least a 50% reduction in the dimensions of the tumour mass and a complete clinical response refers to complete absence of the mass on physical exam, as well as absence of inflammation, ulceration and peau d'orange. | 6 months (approximately) |
| Measure | Description | Time Frame |
|---|---|---|
| Pathologic response | Using the Residual Cancer Burden (RCB) index the pathologic response will be divided into categories. The three categories are complete response, near complete response and chemotherapy resistance. A complete pathologic response (pCR) refers to complete absence of invasive cancer. | 6 months (approximately) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Som Mukherjee | Juravinski Cancer Centre Hamilton, Ontario | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Juravinski Cancer Centre | Hamilton | Ontario | L8V5C2 | Canada | ||
| London Health Sciences Centres - London Regional Cancer Program |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Imaging Quantification |
Fluorothymidine Positron Emission Tomography (FLT PET) and Blood Oxygen Level Dependent (BOLD) MRI quantification of tumor responses to predict which patients are likely to achieve a pathologic complete response. |
| 6 months (approximately) |
| London |
| Ontario |
| Canada |
| Thunder Bay Regional Health Sciences Centre | Thunder Bay | Ontario | P7B6V4 | Canada |
| Sunnybrook Odette Health Sciences Centre | Toronto | Ontario | M4N3M5 | Canada |